Has Dorothy Wang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,070 in general payments to Dorothy Wang, MD across 71 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dorothy Wang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dorothy Wang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dorothy Wang, MD

Otolaryngology · Culver City, CANPI 1497942353

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Davol Inc. accounts for 88.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $16,113 and has fallen 96.5% since, to $564 in 2025. Among otolaryngology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,070in general payments, 2019–2025

Across 71 payments — averaging $353.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Davol Inc.$22K
C. R. Bard, Inc. & Subsidiaries$500
Stryker$430
Regeneron Healthcare Solutions, Inc.$252
GSK$225
Medtronic$205
plus $1K from 16 others

What the payments were for

Consulting fees$11,10044%
Speaking & faculty fees$11,35045%
Travel & lodging$3561%
Food & beverage$2,2639%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Davol Inc.	11	$22,141
C. R. Bard, Inc. & Subsidiaries	1	$500
Stryker	9	$430
Regeneron Healthcare Solutions, Inc.	8	$252
GSK	5	$225
Medtronic	2	$205
Acclarent, Inc	5	$178
Integra Lifesciences Corporation	1	$157
AbbVie	6	$153
Regeneron	1	$129
Neurent Medical Limited	4	$126
Novo Nordisk	1	$124
Optinose US, Inc.	3	$76
Gilead	1	$74
Aerin Medical Inc.	2	$62
Intersect ENT, Inc.	2	$56
Sanofi	2	$45
Smith+Nephew	2	$39
Hikma Pharmaceuticals USA	2	$37
Merz North America, Inc.	1	$26
AstraZeneca	1	$22
KARL Storz Endoscopy-america	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INTEGRA$472
Signia$175
INTEGRA DERMAL REGENERATION TEMPLATE$157
PRIMATRIX$157
ENTELLUS - XPRESS ENT DILATION SYSTEM$135
LIBTAYO$129
DUPIXENT$125

How this compares

$25,070 in reported general payments places this provider in the 95th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California →

Medicare billing

Part B allowed, 2024

$124,366

Medicare patients

316

Services billed

665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ipratropium Bromide	52	$1,504
Azelastine Hcl	37	$685
Fluocinolone Acetonide Oil	13	$525
Fluticasone Propionate	40	$523
Famotidine	36	$282
Clotrimazole	14	$273
Omeprazole	33	$241
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	21	$204
Mupirocin	13	$71
Montelukast Sodium	12	$38
Prednisone	12	$23

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Culver City

Brian WeeksSan Diego$924K
Randall OwRoseville$613K
Amir MoradiVista$389K
Keith BlackwellLos Angeles$349K
Kalpna DurairajSun Valley$348K
Todd MillerNewport Beach$259K
Jeffrey SuhLos Angeles$223K
Dennis TangLos Angeles$209K
Jeffrey FeinfieldThousand Oaks$160K
Jonathan SykesGranite Bay$148K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →